ubject:
Hot Off The Wire: XILLIX TECHNOLOGIES CORP.
Date:
Thu, 08 Apr 1999 12:47:22 -0400
From:
CCN_HOTW@cdn-news.com
To:
CCN_HOTW@cdn-news.com
===================================================================
Canadian Corporate News --- Hot Off The Wire
News Release for XILLIX TECHNOLOGIES CORP.
===================================================================
-------------------------------------------------------------------
E*TRADE Canada
Don't make your investment decisions site unseen.
Sign-up for a free trial membership:
www2.cdn-news.com
Someday we'll all invest this way.
-------------------------------------------------------------------
NEWS RELEASE TRANSMITTED BY CANADIAN CORPORATE NEWS
FOR: XILLIX TECHNOLOGIES CORP.
TSE SYMBOL: XLX
APRIL 8, 1999
Xillix Explores Head and Neck Cancers With Xillix
LIFE-ENT Fluorescence Endoscopy System
RICHMOND, BRITISH COLUMBIA--Xillix has completed feasibility
studies of a new medical device to improve a physician's ability
to detect cancer and pre-cancerous lesions in the head and neck
region at its earliest stages. The device, called the Xillix
LIFE-ENT Fluorescence Endoscopy System (ENT refers to ear, nose
and throat), has been utilized in research conducted at the
University Medical Center, University Department of
Otorhinolaryngology and Cervicofacial Surgery, in Ljublana,
Slovenia. The preliminary results of 150 patients indicated an
improvement in the ability of physicians to detect 96 percent of
the cancerous and pre-cancerous lesion using the Xillix LIFE-ENT
system compared to 72 percent using conventional white light
laryngoscope imaging.
The principal investigators include Executive Member of EUFOS
(European Federation of Otorhinolaryngology Society) and President
of the Slovenian ENT Society Professor Miha Zargi, Ph.D. M.D., and
Igor Fajdiga, M.D. who both practice medicine at the University
Medical Center in Slovenia. "The Xillix LIFE-ENT Fluorescence
Endoscopy System is both a useful and reliable tool in the
diagnosis of laryngeal (larnyx and pharynx) cancers and
pre-cancers," said Dr. Igor Fajdiga.
"We commenced our studies to explore the adaptation of our
proprietary imaging technology to the ENT area in 1996," said Mr.
Pierre Leduc, President and Chief Executive Officer of Xillix.
"We had the opportunity to conduct feasibility studies with these
world leading clinicians in cancer research in ENT. We are
pleased with the strong improvement that our technology can
provide to improve early detection of ENT cancers and are
optimistic that this will improve the outcome of patients who are
afflicted with cancers in this area."
Cancers of the head and neck region include the oral cavity,
pharynx and larynx. This accounts for more than 500,000 new cases
of cancer globally each year and is among the most common cancers
worldwide. In the U.S. the incidence of head and neck cancer is
less than 5 percent of all cancers - however 33 percent of these
patients eventually die from the disease. In the U.S. nearly 95
percent of all head and neck cancers can be attributed to smoking
and alcohol, and most patients are diagnosed with advanced stages
of the disease. Cancers of the head and neck region are commonly
associated with lung cancer and have a high incidence of multiple
lesions.
The Company's lead product; called the Xillix LIFE-Lung
Fluorescence Endoscopy System has received worldwide regulatory
approval and is commercially available. Worldwide marketing and
distribution for the Xillix LIFE-Lung Fluoresce Endoscopy System
and the Xillix LIFE-GI Fluorescence Endoscopy System has been
granted to Olympus Optical Co. Ltd. of Tokyo, the international
endoscopy market leader.
-30-
FOR FURTHER INFORMATION PLEASE CONTACT:
Xillix Technologies Corp.
Laurie McMichael
Manager, Investor Relations
(604) 278-5000
(604) 278-3356 (FAX)
Website: www.xillix.com
Email: lmcm@xillix.com
INDUSTRY: MTC
SUBJECT: NWS
-0-
===================================================================
You may change your service options at anytime by visiting:
cdn-news.com
===================================================================
|
